Lyell Immunopharma misses Q4 revenue estimates
Overview
CAR T-cell therapy developer's Q4 revenue missed analyst expectations
Adjusted net loss for Q4 was narrower than expected, beating analyst estimates
Company closed $50 mln equity tranche after achieving clinical milestone for ronde-cel
Outlook
Company expects current cash to fund operations into Q2 2027 through multiple clinical milestones
Result Drivers
Cash, cash equivalents and marketable securities as of December 31, 2025 were approximately $247.2 million
ACQUISITION-RELATED EXPENSES - Q4 net loss included $66.3 mln in acquired in-process R&D expense and $19.7 mln in stock-based compensation tied to LYL273 license acquisition
COST REDUCTIONS - Lower personnel and facility costs following workforce reduction and technology transfer of ronde-cel partially offset higher R&D expenses
Company press release: ID:nGNX7rqRn7
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Miss | $6,000 | $12,200 (5 Analysts) |
Q4 Adjusted Net Income | Beat | -$33.06 mln | -$47.67 mln (4 Analysts) |
Q4 Net Income |
| -$140.72 mln |
|
Q4 Operating Expenses |
| $127.65 mln |
|
Q4 Operating Income |
| -$127.64 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Lyell Immunopharma Inc is $34.00, about 35.2% above its March 11 closing price of $25.14
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
